

## WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Thursday, July 22, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
--------------	-----------------	--------------	------------------

*DB=USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR*

<input type="checkbox"/>	L3	(paclitaxel) same vial	74
<input type="checkbox"/>	L2	(paclitaxel) same sealed	38
<input type="checkbox"/>	L1	(taxane or taxol or paclitaxal) same sealed	17

END OF SEARCH HISTORY

First Hit Fwd Refs [Generate Collection](#) [Print](#)

L1: Entry 16 of 17

File: USPT

Mar 21, 1995

DOCUMENT-IDENTIFIER: US 5399363 A

TITLE: Surface modified anticancer nanoparticles

Detailed Description Text (46):

Approximately 18 mL of precleaned zirconium oxide media (1 mm) was added to a 30 mL amber jar. To it was added 240 mg of taxol (Sigma Chemicals) and 180 mg of Tween 20. Finally, 12 mL of water for injection was added to the jar, it was sealed and mounted on a roller mill for 11 days. The final particle size was 327 nm. The formulation was stable when exposed to PBS (pH 7.4) and rat plasma.

[First Hit](#) [Fwd Refs](#) [Generate Collection](#) [Print](#)

L1: Entry 15 of 17

File: USPT

May 16, 1995

DOCUMENT-IDENTIFIER: US 5415869 A

TITLE: Taxol formulation

Detailed Description Text (12):

In another method, dried vesicle-forming lipids and taxol, mixed in the appropriate amounts, are dissolved, with warming if necessary, in a suitable organic solvent with a vapor pressure and freezing point sufficiently high to allow removal by freeze-drying (lyophilization). Examples of such solvents are tert-butanol and benzene. The drug/lipid/solvent mixture then is frozen and placed under high vacuum. Examples of methods for freezing include "shell-freezing", in which the container containing the drug/lipid/solvent mixture is swirled or spun to maximize contact of the liquid with the walls of the vessel, and the container is placed in a cooled substance such as liquid nitrogen or carbon dioxide ice mixed with a solvent such as an alcohol or acetone. The mixture thus is frozen rapidly without segregation of the constituents of the drug/lipid/solvent mixture. A fluffy, dry powder results from removal of the solvent by lyophilization. This drug/lipid powder may be stored for extended periods under conditions that reduce chemical degradation of the constituents or the absorption of moisture. Examples of such conditions include sealed under an atmosphere of dry, inert gas (such as argon or nitrogen), and storage in the cold. When it is desired to administer the material, reconstitution is performed by adding a physiologically compatible aqueous medium, preferably a pyrogen-free physiological saline or 5% dextrose in water, as used for parenteral fluid replacement. Reconstitution causes the spontaneous formation of liposomes, which may be refined in size by methods detailed below.

[First Hit](#) [Fwd Refs](#) [Generate Collection](#) [Print](#)

L1: Entry 15 of 17

File: USPT

May 16, 1995

US-PAT-NO: 5415869

DOCUMENT-IDENTIFIER: US 5415869 A

TITLE: Taxol formulation

DATE-ISSUED: May 16, 1995

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Straubinger; Robert M.	Amherst	NY		
Sharma; Amarnath	Buffalo	NY		
Mayhew; Eric	South Wales	NY		

US-CL-CURRENT: 424/450

## CLAIMS:

## What is claimed:

## 1. A pharmaceutical composition for use in treatment of cancer comprising:

at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and

a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective ratio of 1:9 to 3:7, wherein said mixture entraps said at least one taxane and said composition is in the form of particles having a size of 0.025 to 10 microns with a substantial absence of taxane crystal formation in said composition.

2. A pharmaceutical composition according claim 1, wherein the negatively charged phospholipid is selected from the group consisting of phosphatidyl inositol, phosphatidyl serine, phosphatidyl glycerol, phosphaphatic acid, diphosphatidyl glycerol, poly(ethylene glycol)-phosphatidyl ethanolamine, dimyristoylphosphatidyl glycerol, dioleoylphosphatidyl glycerol, dilauryloylphosphatidyl glycerol, dipalmitoylphosphatidyl glycerol, distearoyloylphosphatidyl glycerol, dimyristoyl phosphatic acid, dipalmitoyl phosphatic acid, dimyristoyl phosphatidyl serine, dipalmitoyl phosphatidyl serine, brain phosphatidyl serine, and mixtures thereof.

3. A pharmaceutical composition according to claim 1, wherein the zwitterion phospholipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, sphingomyelin, lecithin, lysolecithin, lysophatidylethanolamine, cerebrosides, dimyristoylphosphatidyl choline, dipalmitoylphosphatidyl choline, distearoyloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, 1-myristoyl-2-palmitoyl phosphatidyl choline, 1-palmitoyl-2-myristoyl phosphatidyl

choline, 1-palmitoyl-2-stearoyl phosphatidyl choline, 1-stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and mixtures thereof.

4. A pharmaceutical composition according to claim 1, wherein the negatively charged phospholipid is phosphatidyl glycerol and the zwitterion phospholipid is phosphatidyl choline.
5. A pharmaceutical composition according to claim 1, wherein said composition contains 1.5-3.3 mol % of said taxane.
6. A pharmaceutical composition according to claim 1, wherein said taxane is selected from the group consisting of taxol, 7-epitaxol, 7-acetyl taxol, 10-desacetyltaxol, 10-desacetyl-7-epitaxol, 7-xylosyltaxol, 10-desacetyl-7-glutaryltaxol, 7-N,N-dimethylglycyltaxol, 7-L-alanyltaxol, taxotere, and mixtures thereof.
7. A pharmaceutical composition according to claim 1 further comprising:  
a sterol.
8. A pharmaceutical composition according to claim 7, wherein said sterol is selected from the group consisting of cholesterol, cholesterol derivatives, vitamin D, phytosterols, steroid hormones, cholestryl esters, and mixtures thereof.
9. A pharmaceutical composition according to claim 7, wherein said composition contains 0.01 to 50 mol % of said sterol.
10. A pharmaceutical composition according to claim 1, wherein said composition is in dry, lyophilized form.
11. A pharmaceutical composition according to claim 1, wherein said composition is a liquid suspension.
12. A method of treating cancer patients comprising:  
administering to a cancer patient said pharmaceutical composition according to claim 1 in an effective amount.
13. A pharmaceutical composition for use in treatment of cancer comprising:  
at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and  
a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective ratio of 1:9 to 3:7, wherein said mixture forms liposomes which entrap said at least one taxane and said composition is in the form of particles having a size of 0.025 to 10 microns with a substantial absence of taxane crystal formation in said composition.
14. A pharmaceutical composition according to claim 13, wherein the negatively charged phospholipid is selected from the group consisting of phosphatidyl inositol, phosphatidyl serine,

phosphatidyl glycerol, phosphaphatic acid, diphosphatidyl glycerol, poly(ethylene glycol)-phosphatidyl ethanolamine, dimyristoylphosphatidyl glycerol, dioleoylphosphatidyl glycerol, dilauryloylphosphatidyl glycerol, dipalmitoylphosphatidyl glycerol, distearyloylphosphatidyl glycerol, dimyristoyl phosphatic acid, dipalmitoyl phosphatic acid, dimyristoyl phosphitadyl serine, dipalmitoyl phosphatidyl serine, brain phosphatidyl serine, and mixtures thereof.

15. A pharmaceutical composition according to claim 13, wherein the zwitterion phospholipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, sphingomyelin, lecithin, lysolecithin, lysophatidylethanolamine, cerebrosides, dimyristoylphosphatidyl choline, dipalmitoylphosphatidyl choline, distearyloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, 1-myristoyl-2-palmitoyl phosphatidyl choline, 1-palmitoyl-2-myristoyl phosphatidyl choline, 1-palmitoyl-2-stearoyl phosphatidyl choline, 1-stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and mixtures thereof.

16. A pharmaceutical composition according to claim 13, wherein said taxane is selected from the group consisting of taxol, 7-epitaxol, 7-acetyl taxol, 10-desacetyltaxol, 10-desacetyl-7-epitaxol, 7-xylosyltaxol, 10-desacetyl-7-sylosyltaxol, 7-glutaryltaxol, 7-N,N-dimethylglycyctaxol, 7-L-alanyltaxol, taxotere, and mixtures thereof.

17. A pharmaceutical composition according to claim 13, wherein said composition is in the form of particles having a size of 1 to 5 microns.

18. A method of treating cancer patients comprising:

administering to a cancer patient said pharmaceutical composition according to claim 13 in an effective amount.

19. A pharmaceutical composition in particulate form for use in treatment of cancer comprising:

at least one taxane present in said composition in a pharmaceutically effective amount of 1.5-8.0 mol % and

a mixture of one or more negatively charged phospholipids and one or more zwitterion phospholipids in a respective molar ratio of 1:9 to 3:7, wherein said mixture entraps said at least one taxane within particles having a size of 1 to 5 microns with a substantial absence of taxane crystal formation in said composition.

20. A pharmaceutical composition according claim 19, wherein the negatively charged phospholipid is selected from the group consisting of phosphatidyl inositol, phosphatidyl serine, phosphatidyl glycerol, phosphaphatic acid, diphosphatidyl glycerol, poly(ethylene glycol)-phosphatidyl ethanolamine, dimyristoylphosphatidyl glycerol, dioleoylphosphatidyl glycerol, dilauryloylphosphatidyl glycerol, dipalmitoylphosphatidyl glycerol, distearyloylphosphatidyl glycerol, dimyristoyl phosphatic acid, dipalmitoyl phosphatic acid, dimyristoyl phosphitadyl serine, dipalmitoyl phosphatidyl serine, brain phosphatidyl serine, and mixtures thereof.

21. A pharmaceutical composition according to claim 19, wherein the zwitterion phospholipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, sphingomyelin, lecithin, lysolecithin, lysophatidylethanolamine, cerebrosides,

dimyristoylphosphatidyl choline, dipalmitoylphosphatidyl choline, distearylloylphosphatidyl choline, dielaidoylphosphatidyl choline, dioleoylphosphatidyl choline, dilauryloylphosphatidyl choline, 1-myristoyl-2-palmitoyl phosphatidyl choline, 1-palmitoyl-2-myristoyl phosphatidyl choline, 1-palmitoyl-2-stearoyl phosphatidyl choline, 1-stearoyl-2-palmitoyl phosphatidyl choline, dimyristoyl phosphatidyl ethanolamine, dipalmitoyl phosphatidyl ethanolamine, brain sphingomyelin, dipalmitoyl sphingomyelin, distearoyl sphingomyelin, and mixtures thereof.

22. A pharmaceutical composition according to claim 19, wherein said taxane is selected from the group consisting of taxol, 7-epitaxol, 7-acetyl taxol, 10-desacetyltaxol, 10-desacetyl-7-epitaxol, 7-xylosyltaxol, 10-desacetyl-7-sylosyltaxol, 7-glutaryltaxol, 7-N,N-dimethylglycytaxol, 7-L-alanyltaxol, taxotere, and mixtures thereof.

23. A pharmaceutical composition according to claim 19 further comprising:

a sterol.

24. A method of treating cancer patients comprising:

administering to a cancer patient said pharmaceutical composition according to claim 19 in an effective amount.

[First Hit](#) [Fwd Refs](#) [Generate Collection](#) [Print](#)

L1: Entry 13 of 17

File: USPT

Apr 2, 1996

DOCUMENT-IDENTIFIER: US 5504102 A

TITLE: Stabilized pharmaceutical composition and stabilizing solvent

Detailed Description Text (7):

Samples 8-21 were prepared by dissolving 6 mg/ml of paclitaxel in 50:50 v/v mixture of processed Cremophor EL and dehydrated ethanol. The Cremophor EL of samples 8-21 was processed as discussed above in Example 1. Sample 22 was prepared as a control sample from unprocessed Cremophor EL in a 50:50 v/v mixture with paclitaxel in the amount of 6 mg/ml. Each of the samples 8-20 were mixed with the components listed in Tables 2 and 3. Three ml aliquots of the test samples were placed in 6 cc Type I flint glass vials. The vials were stoppered with West 4455/45 Teflon-faced stoppers, sealed and stored for four weeks at 50.degree. C., and then analyzed by HPLC for Taxol concentration. The control parameters of the HPLC are as follows:

[First Hit](#) [Fwd Refs](#) [Generate Collection](#) [Print](#)

L1: Entry 13 of 17

File: USPT

Apr 2, 1996

US-PAT-NO: 5504102

DOCUMENT-IDENTIFIER: US 5504102 A

TITLE: Stabilized pharmaceutical composition and stabilizing solvent

DATE-ISSUED: April 2, 1996

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Agharkar, Shreeram N.	Fayetteville	NY		
Gogate, Uday S.	East Syracuse	NY		

US-CL-CURRENT: 514/449

## CLAIMS:

What is claimed is:

1. A stabilized composition comprising an antineoplastic compound selected from the group consisting of teniposide, paclitaxel, camptothecin and derivatives thereof; and a solvent capable of dispersing or solubilizing said antineoplastic compound comprising polyoxyethylated castor oil and sufficient acid to provide said solvent with a carboxylate anion content less than or equal to  $0.6 \times 10^{-6}$  g equivalents of carboxylate anion per ml of solvent.
2. The composition of claim 1 wherein said solvent further comprises an alcohol.
3. The composition of claim 1 wherein said solvent is a mixture of ethyl alcohol, acid and said polyoxyethylated castor oil.
4. The composition of claim 1 wherein said polyoxyethylated castor oil is a condensation product of castor oil and 20-40 moles of ethylene oxide per mole of castor oil.
5. The composition of claim 1 wherein said acid is a mineral acid.
6. The composition of claim 1 wherein said acid is selected from the group consisting of HCl, HBr, HI, HF, H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub> and acetic acid.
7. The composition of claim 1 wherein said solvent contains a mineral acid in an amount to provide about  $5.6 \times 10^{-6}$  to  $8.4 \times 10^{-6}$  g of H<sup>+</sup> per ml of solvent.
8. The composition of claim 1 wherein said antineoplastic compound is teniposide.
9. The composition of claim 1 wherein said antineoplastic compound is camptothecin.

10. A method of preparing a stabilized composition comprising preparing a solvent comprising a polyoxyethylated castor oil and sufficient acid to provide said solvent with a carboxylate anion content less than or equal to 0.6.times.10.sup.-6 g equivalents of carboxylate anion per ml of solvents, and dispersing an antineoplastic compound selected from the group consisting of teniposide, paclitaxel, camptothecin and derivatives thereof in said solvent.

11. The method of claim 10 wherein said solvent further comprises an alcohol.

12. The method of claim 10 wherein said solvent is a mixture of ethyl alcohol, acid and said polyoxyethylated castor oil.

13. The method of claim 10 wherein said polyoxyethylated castor oil is a condensation product of castor oil, and 20-40 moles of ethylene oxide per mole of castor oil.

14. The method of claim 10 wherein said acid is a mineral acid.

15. The method of claim 10 wherein said acid is selected from the group consisting of HCl, HBr, HI, HF, H<sub>2</sub>SO<sub>4</sub>, HNO<sub>3</sub> and acetic acid.

16. The method of claim 10 wherein said solvent contains a mineral acid in an amount to provide about 5.6.times.10.sup.-6 to 8.4.times.10.sup.-6 g of H<sup>+</sup> per ml of solvent.

17. The method of claim 10 wherein said antineoplastic compound is teniposide.

18. The method of claim 10 wherein said antineoplastic compound is camptothecin.

19. A stabilized composition comprising paclitaxel and a solvent capable of dispersing or solubilizing said paclitaxel comprising polyoxyethylated castor oil and sufficient acid to provide said solvent with a carboxylate anion content less than or equal to 0.6.times.10.sup.-6 g equivalents of carboxylate anion per ml of solvent.

20. A method of preparing a stabilized composition comprising preparing a solvent comprising a polyoxyethylated castor oil and sufficient acid to provide said solvent with a carboxylate anion content less than or equal to 0.6.times.10.sup.-6 g equivalents of carboxylate anion per ml of solvents, and dispersing paclitaxel in said solvent.

[First Hit](#) [Fwd Refs](#) [Generate Collection](#) [Print](#)

L1: Entry 10 of 17

File: USPT

Jul 13, 1999

DOCUMENT-IDENTIFIER: US 5922754 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Pharmaceutical compositions containing paclitaxel

Detailed Description Text (15):

Paclitaxel and many taxane analogs degrade in ethanolic solutions to which surfactants like Cremophor have been added. Typically, a shelf life of the formulation is analytically determined after storing the formulation at elevated temperatures for 40.degree. C. over days or months. In the present case, the room temperature stability of the compositions of the invention was estimated by employing the following procedure. Five mL of the formulation was transferred to a 5 mL vials, each vial stoppered with a Teflon-coated stopper and then crimp sealed with aluminum crimps. The sealed vial was then heated either at 60.degree. C. or more preferably at 70.degree. C. for 16 to 24 hours and then cooled to room temperature. The resulting solution was diluted in a suitable diluting solvent and analyzed by high performance liquid chromatography (HPLC). As it is known that paclitaxel will degrade at high temperatures to form baccatin III and side ethyl ester due to the cleavage of the side chain at C-13, as well as other impurities like base-catalyzed epimerization of paclitaxel (e.g., 7-epitaxol), HPLC was used to determine the individual degradants and total of all degradants as a function of time and temperature. All reagents used for chromatography are HPLC grade. The HPLC system utilized a Thermoseparation P 4000 ternary solvent Pump, AS 3000 Autoinjector and Applied Biosystem 785A programmable wavelength detector in sequence with Fisons VG chromatography server data acquisition system connected to a computer containing Fison's Xchrom software for data integration. The analytical column used is Phenomenex, Curosil PFP, 5 micron 25 cm.times.4.6 mm ID column. A Curosil PFP, 30 mm.times.4.6 mm guard column is connected in series to the inlet side of the analytical column though a VICCI, Valco instruments automatic column switching device. The gradient mobile phase system consists of 40:60 acetonitrile: -0.1% phosphoric acid mobile phase A and 60:40 acetonitrile: 0.1% phosphoric acid mobile phase B. The gradient conditions between the two mobile phases are adjusted such that the late-eluting 7-epitaxol can be monitored. The guard column is flushed with 50:50 mixture of the above two mobile phases. The flow rate is 1.5 mL per minute through the analytical column, while the flow rate through the second pump used for clean up was maintained at 0.5 mL per minute. An injection volume of 20 microliters was employed. The eluting peaks were monitored at a wavelength of 227 nm. The method involves injection of the suitably diluted sample through the guard column connected to the analytical column. The mobile phase flows through the guard column and then through the analytical column. The mobile phase flow through the two columns in series is maintained for a suitable duration such that all the impurities move from the guard column to the analytical column. After this run time, the guard column connection to the analytical column is cut off and the mobile phase flow continues through the analytical column only. While chromatographic separation is accomplished in the analytical column, the guard column is flushed to remove surfactants via a flushing solution and another pump.

## Hit List

<a href="#">Clear</a>	<a href="#">Generate Collection</a>	<a href="#">Print</a>	<a href="#">Fwd Refs</a>	<a href="#">Bkwd Refs</a>
<a href="#">Generate OACS</a>				

### Search Results - Record(s) 1 through 17 of 17 returned.

1. Document ID: US 6764830 B1

L1: Entry 1 of 17

File: USPT

Jul 20, 2004

US-PAT-NO: 6764830

DOCUMENT-IDENTIFIER: US 6764830 B1

TITLE: Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins

DATE-ISSUED: July 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sakowicz; Roman	Foster City	CA		
Goldstein; Lawrence S. B.	San Diego	CA		

US-CL-CURRENT: 435/19; 435/196

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	-------------------------

2. Document ID: US 6723840 B1

L1: Entry 2 of 17

File: USPT

Apr 20, 2004

US-PAT-NO: 6723840

DOCUMENT-IDENTIFIER: US 6723840 B1

TITLE: Identification and expression of a novel kinesin motor protein

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sakowicz; Roman	Foster City	CA		
Goldstein; Lawrence S. B.	San Diego	CA		

US-CL-CURRENT: 536/23.74; 424/130.1, 424/184.1, 424/185.1, 424/195.15, 424/278.1,  
424/93.5, 435/203, 435/254.2, 435/454 , 530/388.5

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	-------------------------

3. Document ID: US 6645748 B1

L1: Entry 3 of 17

File: USPT

Nov 11, 2003

US-PAT-NO: 6645748

DOCUMENT-IDENTIFIER: US 6645748 B1

TITLE: Plus end-directed microtubule motor required for chromosome congression

DATE-ISSUED: November 11, 2003

## INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wood; Kenneth W.	Foster City	CA		
Sakowicz; Roman	Foster City	CA		
Goldstein; Lawrence S. B.	San Diego	CA		
Cleveland; Don W.	Delmar	CA		

US-CL-CURRENT: 435/194; 435/184, 435/4, 435/7.1, 435/975, 530/350, 530/387.1

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KINIC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	-----------------------	-------------------------

 4. Document ID: US 6602902 B2

L1: Entry 4 of 17

File: USPT

Aug 5, 2003

US-PAT-NO: 6602902

DOCUMENT-IDENTIFIER: US 6602902 B2

\*\* See image for Certificate of Correction \*\*

TITLE: Dha-pharmaceutical agent conjugates to improve tissue selectivity

DATE-ISSUED: August 5, 2003

## INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles E.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		
Bradley; Matthews O.	Layton	PA		

US-CL-CURRENT: 514/449; 424/523, 514/169, 514/549, 514/552, 514/558, 514/560

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KINIC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	-----------------------	-------------------------

 5. Document ID: US 6576636 B2

L1: Entry 5 of 17

File: USPT

Jun 10, 2003

US-PAT-NO: 6576636

DOCUMENT-IDENTIFIER: US 6576636 B2

TITLE: Method of treating a liver disorder with fatty acid-antiviral agent conjugates

DATE-ISSUED: June 10, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Webb; Nigel L.	Bryn Mawr	PA		
Bradley; Matthews O.	Laytonsville	MD		
Swindell; Charles S.	Merion	PA		
Shashoua; Victor E.	Brookline	MA		

US-CL-CURRENT: 514/263.38; 514/120, 514/395, 514/418, 514/43, 514/45, 514/49,  
514/50, 514/54, 514/651, 514/659, 514/662

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

6. Document ID: US 6541508 B2

L1: Entry 6 of 17

File: USPT

Apr 1, 2003

US-PAT-NO: 6541508

DOCUMENT-IDENTIFIER: US 6541508 B2

TITLE: Taxane prodrugs

DATE-ISSUED: April 1, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ekwuribe; Nnochiri N.	Cary	NC		
Price; Christopher H.	Chapel Hill	NC		
Bartley; Gary S.	Florence	SC		

US-CL-CURRENT: 514/449; 528/421, 549/510, 549/511

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

7. Document ID: US 6506405 B1

L1: Entry 7 of 17

File: USPT

Jan 14, 2003

US-PAT-NO: 6506405

DOCUMENT-IDENTIFIER: US 6506405 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Methods and formulations of cremophor-free taxanes

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Desai; Neil P.	Los Angeles	CA		
Soon-Shiong; Patrick	Los Angeles	CA		

US-CL-CURRENT: 424/450; 424/422, 424/426, 424/428, 424/455, 424/481, 424/491,  
424/497

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

---

8. Document ID: US 6380405 B1

L1: Entry 8 of 17

File: USPT

Apr 30, 2002

US-PAT-NO: 6380405

DOCUMENT-IDENTIFIER: US 6380405 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Taxane prodrugs

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ekwuribe; Nnochiri	Cary	NC		
Bartley; Gary S.	Durham	NC		
Price; Christopher H.	Chapel Hill	NC		

US-CL-CURRENT: 549/510; 549/511

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

---

9. Document ID: US 6080877 A

L1: Entry 9 of 17

File: USPT

Jun 27, 2000

US-PAT-NO: 6080877

DOCUMENT-IDENTIFIER: US 6080877 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Taxanes

DATE-ISSUED: June 27, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Swindell; Charles S.	Merion	PA		
Shashoua; Victor E.	Brookline	MA		

Bradley; Matthews O.	Laytonsville	MD
Webb; Nigel L.	Bryn Mawr	PA

US-CL-CURRENT: 549/510; 549/511

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

---

10. Document ID: US 5922754 A

L1: Entry 10 of 17

File: USPT

Jul 13, 1999

US-PAT-NO: 5922754

DOCUMENT-IDENTIFIER: US 5922754 A

\*\* See image for Certificate of Correction \*\*

TITLE: Pharmaceutical compositions containing paclitaxel

DATE-ISSUED: July 13, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burchett; Mark K.	Waukegan	IL		
Coddington; Cynthia A.	Gurnee	IL		
Raghavan; Rajagopalan	Grayslake	IL		
Speicher; Earl R.	Buffalo Grove	IL		

US-CL-CURRENT: 514/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

---

11. Document ID: US 5919815 A

L1: Entry 11 of 17

File: USPT

Jul 6, 1999

US-PAT-NO: 5919815

DOCUMENT-IDENTIFIER: US 5919815 A

TITLE: Taxane compounds and compositions

DATE-ISSUED: July 6, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bradley; Matthews O.	Laytonsville	MD		
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles S.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		

US-CL-CURRENT: 514/449; 549/510

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

12. Document ID: US 5795909 A

L1: Entry 12 of 17

File: USPT

Aug 18, 1998

US-PAT-NO: 5795909

DOCUMENT-IDENTIFIER: US 5795909 A

TITLE: DHA-pharmaceutical agent conjugates of taxanes

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles S.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		
Bradley; Matthews O.	Laytonsville	MD		

US-CL-CURRENT: 514/449; 514/549

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

13. Document ID: US 5504102 A

L1: Entry 13 of 17

File: USPT

Apr 2, 1996

US-PAT-NO: 5504102

DOCUMENT-IDENTIFIER: US 5504102 A

TITLE: Stabilized pharmaceutical composition and stabilizing solvent

DATE-ISSUED: April 2, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Agharkar; Shreeram N.	Fayetteville	NY		
Gogate; Uday S.	East Syracuse	NY		

US-CL-CURRENT: 514/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

14. Document ID: US 5494683 A

L1: Entry 14 of 17

File: USPT

Feb 27, 1996

US-PAT-NO: 5494683

DOCUMENT-IDENTIFIER: US 5494683 A

TITLE: Surface modified anticancer nanoparticles

DATE-ISSUED: February 27, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Liversidge; Gary G.	West Chester	PA		
Liversidge; Elaine	West Chester	PA		
Sarpotdar; Pramod P.	Malvern	PA		

US-CL-CURRENT: 424/490; 424/487, 424/495, 424/499

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequence](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. De](#)

---

15. Document ID: US 5415869 A

L1: Entry 15 of 17

File: USPT

May 16, 1995

US-PAT-NO: 5415869

DOCUMENT-IDENTIFIER: US 5415869 A

TITLE: Taxol formulation

DATE-ISSUED: May 16, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Straubinger; Robert M.	Amherst	NY		
Sharma; Amarnath	Buffalo	NY		
Mayhew; Eric	South Wales	NY		

US-CL-CURRENT: 424/450

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequence](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. De](#)

---

16. Document ID: US 5399363 A

L1: Entry 16 of 17

File: USPT

Mar 21, 1995

US-PAT-NO: 5399363

DOCUMENT-IDENTIFIER: US 5399363 A

TITLE: Surface modified anticancer nanoparticles

DATE-ISSUED: March 21, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Liversidge; Gary G.	West Chester	PA
Liversidge; Elaine	West Chester	PA
Sarpotdar; Pramod P.	Malvern	PA

US-CL-CURRENT: 424/490; 424/489

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [SEQUENCES](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [DRAFT](#)

17. Document ID: US 20030065022 A1, WO 9412030 A1, AU 9351967 A, AU 9456126 A, ZA 9308844 A, CN 1095266 A, NZ 258044 A, AU 667142 B, CN 1096673 A, EP 835657 A1, US 5733888 A, ES 2119996 T3, US 5972992 A, US 5977164 A, CA 2308082 A1, US 6140359 A, US 6306894 B1

L1: Entry 17 of 17

File: DWPI

Apr 3, 2003

DERWENT-ACC-NO: 1994-199826

DERWENT-WEEK: 200325

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Injectable antineoplastic taxol compsns. with improved stability - contain taxol in polyethoxylated castor oil adjusted to pH below 8.1

INVENTOR: CARVER, D; ELLIOTT, R L ; EWALD, H ; HANDRECK, G P ; PROUT, T ; CARVER, D R ; PROUT, T R ; ELLIOTT, R ; HANDRECK, P

PRIORITY-DATA: 1992US-0995501 (December 22, 1992), 1992AU-0006074 (November 27, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030065022 A1</u>	April 3, 2003		000	A61K031/337
<u>WO 9412030 A1</u>	June 9, 1994		009	A01N043/02
<u>AU 9351967 A</u>	June 9, 1994		000	A61K031/335
<u>AU 9456126 A</u>	June 22, 1994		000	A01N043/02
<u>ZA 9308844 A</u>	September 28, 1994		008	A61K000/00
<u>CN 1095266 A</u>	November 23, 1994		000	A61K031/335
<u>NZ 258044 A</u>	December 21, 1995		000	A61K035/78
<u>AU 667142 B</u>	March 7, 1996		000	A61K031/335
<u>CN 1096673 A</u>	December 28, 1994		000	A61K031/335
<u>EP 835657 A1</u>	April 15, 1998	E	007	A61K031/335
<u>US 5733888 A</u>	March 31, 1998		004	A01D043/02
<u>ES 2119996 T3</u>	October 16, 1998		000	A61K031/335
<u>US 5972992 A</u>	October 26, 1999		000	A01D043/02
<u>US 5977164 A</u>	November 2, 1999		000	A01D043/02
<u>CA 2308082 A1</u>	June 9, 1994	E	000	A61K031/335
<u>US 6140359 A</u>	October 31, 2000		000	A01D043/02
<u>US 6306894 B1</u>	October 23, 2001		000	A61K031/335

US 6306894 B1 INT-CL (IPC) : A01 D 43/02; A01 N 43/02; A61 J 1/00; A61 K 0/00; A61 K 9/08; A61 K 31/19; A61 K 31/335; A61 K 31/337; A61 K 35/78; A61 K 47/02; A61 K 47/10; A61 K 47/12; A61 K 47/14; A61 K 47/44; C07 D 305/14

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn De](#)

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

Terms	Documents
(taxane or taxol or paclitaxal) same sealed	17

Display Format:  [Change Format](#)

[Previous Page](#)    [Next Page](#)    [Go to Doc#](#)

## Hit List

---

<a href="#">Clear</a>	<a href="#">Generate Collection</a>	<a href="#">Print</a>	<a href="#">Fwd Refs</a>	<a href="#">Bkwd Refs</a>
<a href="#">Generate OACS</a>				

---

### Search Results - Record(s) 31 through 38 of 38 returned.

---

31. Document ID: US 5716981 A

L2: Entry 31 of 38

File: USPT

Feb 10, 1998

US-PAT-NO: 5716981

DOCUMENT-IDENTIFIER: US 5716981 A

TITLE: Anti-angiogenic compositions and methods of use

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA
Arsenault; A. Larry	Paris			CA

US-CL-CURRENT: 514/449, 128/898, 526/304, 528/421, 604/20, 604/21, 604/269,  
604/508, 606/198, 623/1.15

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	-------------------------

---

32. Document ID: US 5504102 A

L2: Entry 32 of 38

File: USPT

Apr 2, 1996

US-PAT-NO: 5504102

DOCUMENT-IDENTIFIER: US 5504102 A

TITLE: Stabilized pharmaceutical composition and stabilizing solvent

DATE-ISSUED: April 2, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Agharkar; Shreeram N.	Fayetteville	NY		
Gogate; Uday S.	East Syracuse	NY		

US-CL-CURRENT: 514/449

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Drawn D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	-------------------------

33. Document ID: GB 2388025 A

L2: Entry 33 of 38

File: EPAB

Nov 5, 2003

PUB-N0: GB002388025A

DOCUMENT-IDENTIFIER: GB 2388025 A

TITLE: Kit for preparing a formulation of paclitaxel

PUBN-DATE: November 5, 2003

## INVENTOR- INFORMATION:

NAME	COUNTRY
ORTNER, PETER	DE

INT-CL (IPC): A61 K 47/44; A61 K 31/337; A61 K 47/12

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [Claims](#) [KMC](#) [Drawn D](#) 34. Document ID: DE 19925211 A1

L2: Entry 34 of 38

File: EPAB

Dec 7, 2000

PUB-N0: DE019925211A1

DOCUMENT-IDENTIFIER: DE 19925211 A1

TITLE: Kit for preparing stable paclitaxel formulation for use as anticancer agent, comprising separately stored drug, solution of anhydrous citric acid in ethanol and solution of polyethoxylated castor oil in ethanol

PUBN-DATE: December 7, 2000

## INVENTOR- INFORMATION:

NAME	COUNTRY
ORTNER, PETER	DE

INT-CL (IPC): A61 K 9/08; A61 K 31/335

EUR-CL (EPC): A61K047/34; A61K031/337, A61K047/12

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [Claims](#) [KMC](#) [Drawn D](#) 35. Document ID: US 6753006 B1

L2: Entry 35 of 38

File: DWPI

Jun 22, 2004

DERWENT-ACC-NO: 2004-447356

DERWENT-WEEK: 200442

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Unit dosage form for paclitaxel, comprises sealed vial that contains a quantity of non-crystalline, cremophor-free paclitaxel suitable for administration to a human patient over an administration period no greater than three hours

INVENTOR: DESAI, N P; SOON-SHIONG, P

PRIORITY-DATA: 2000US-0629501 (July 31, 2000), 1993US-0023698 (February 22, 1993), 1994US-0200235 (February 22, 1994), 1995US-0485448 (June 7, 1995), 1996US-0720756 (October 1, 1996), 1997US-0926155 (September 9, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6753006 B1</u>	June 22, 2004		018	A61F013/00

INT-CL (IPC): A61 F 13/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw](#) | [De](#)

36. Document ID: US 6710195 B2, WO 2003045326 A2, US 20030153614 A1, AU 2002351169 A1

L2: Entry 36 of 38

File: DWPI

Mar 23, 2004

DERWENT-ACC-NO: 2003-597979

DERWENT-WEEK: 200421

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Preparation of a pharmaceutical composition involves aging polyoxyethylated castor oil by exposing to oxygen

INVENTOR: GORE, A Y; JOSHI-HANGAL, R ; REDKAR, S ; RUBINFELD, J

PRIORITY-DATA: 2001US-333459P (November 26, 2001), 2002US-0306824 (November 26, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6710195 B2</u>	March 23, 2004		000	C07C051/16
<u>WO 2003045326 A2</u>	June 5, 2003	E	019	A61K000/00
<u>US 20030153614 A1</u>	August 14, 2003		000	A61K031/337
<u>AU 2002351169 A1</u>	June 10, 2003		000	A61K000/00

INT-CL (IPC): A61 K 0/00; A61 K 31/337; C07 C 51/16; C07 C 51/34

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw](#) | [De](#)

37. Document ID: US 20030099674 A1

L2: Entry 37 of 38

File: DWPI

May 29, 2003

DERWENT-ACC-NO: 2003-730141

DERWENT-WEEK: 200369

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Porous lyophilized formulation containing taxoid drug(s), can be readily reconstituted into injectable suspension or emulsion by mixing with water using mild agitation that does not require machine processing

INVENTOR: CHEN, A X

PRIORITY-DATA: 2001US-311302P (August 11, 2001), 2002US-0218083 (August 12, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20030099674 A1</u>	May 29, 2003		018	A61K031/7048

INT-CL (IPC): A61 K 9/00; A61 K 31/337; A61 K 31/7048

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

---

38. Document ID: DE 19925211 A1

L2: Entry 38 of 38

File: DWPI

Dec 7, 2000

DERWENT-ACC-NO: 2001-062579

DERWENT-WEEK: 200108

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Kit for preparing stable paclitaxel formulation for use as anticancer agent, comprising separately stored drug, solution of anhydrous citric acid in ethanol and solution of polyethoxylated castor oil in ethanol

INVENTOR: ORTNER, P

PRIORITY-DATA: 1999DE-1025211 (June 1, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 19925211 A1</u>	December 7, 2000		003	A61K009/08

INT-CL (IPC): A61 K 9/08; A61 K 31/335

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn D](#)

[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

Terms	Documents
(paclitaxel) same sealed	38

Display Format: [-] [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

## Hit List

<a href="#">Clear</a>	<a href="#">Generate Collection</a>	<a href="#">Print</a>	<a href="#">Fwd Refs</a>	<a href="#">Bkwd Refs</a>
<a href="#">Generate OACS</a>				

Search Results - Record(s) 1 through 30 of 38 returned.

1. Document ID: US 6759431 B2

L2: Entry 1 of 38

File: USPT

Jul 6, 2004

US-PAT-NO: 6759431

DOCUMENT-IDENTIFIER: US 6759431 B2

TITLE: Compositions and methods for treating or preventing diseases of body passageways

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA

US-CL-CURRENT: 514/449; 424/403, 424/426, 424/501

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [Claims](#) [KMC](#) [Draw](#) [De](#)

2. Document ID: US 6759206 B1

L2: Entry 2 of 38

File: USPT

Jul 6, 2004

US-PAT-NO: 6759206

DOCUMENT-IDENTIFIER: US 6759206 B1

TITLE: System for cell-based screening

DATE-ISSUED: July 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rubin; Richard A.	Pittsburgh	PA		
Giuliano; Kenneth A.	Pittsburgh	PA		
Gough; Albert H.	Glenshaw	PA		
Dunlay; R. Terry	New Kensington	PA		

US-CL-CURRENT: 435/7.2; 435/174, 435/283.1, 435/29, 435/325, 435/40.51, 435/5,  
435/7.1, 435/7.21, 436/172, 436/501, 436/546, 436/800, 436/809

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. De](#)

---

3. Document ID: US 6756207 B1

L2: Entry 3 of 38

File: USPT

Jun 29, 2004

US-PAT-NO: 6756207

DOCUMENT-IDENTIFIER: US 6756207 B1

TITLE: System for cell-based screening

DATE-ISSUED: June 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Giuliano; Kenneth A.	Pittsburgh	PA		
Bright; Gary	Allison Park	PA		
Olson; Keith	Pittsburgh	PA		
Burroughs Tencza; Sarah	Pittsburgh	PA		

US-CL-CURRENT: 435/7.2; 435/287.8, 435/287.9, 435/288.3, 435/288.4, 435/29,  
435/40.5, 435/40.51, 435/7.21, 436/164, 436/172, 436/518, 436/527, 436/546, 436/63,  
436/800, 436/809, 530/300, 530/350, 536/23.1, 536/23.4, 536/23.5, 536/23.53

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. De](#)

---

4. Document ID: US 6753006 B1

L2: Entry 4 of 38

File: USPT

Jun 22, 2004

US-PAT-NO: 6753006

DOCUMENT-IDENTIFIER: US 6753006 B1

TITLE: Paclitaxel-containing formulations

DATE-ISSUED: June 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Desai; Neil P.	Los Angeles	CA		
Soon-Shiong; Patrick	Los Angeles	CA		

US-CL-CURRENT: 424/422; 424/400, 424/451, 424/484

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Draw. De](#)

---

5. Document ID: US 6727071 B1

L2: Entry 5 of 38

File: USPT

Apr 27, 2004

US-PAT-NO: 6727071  
DOCUMENT-IDENTIFIER: US 6727071 B1

TITLE: System for cell-based screening

DATE-ISSUED: April 27, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dunlay; R. Terry	New Kensington	PA		
Taylor; D. Lansing	Pittsburgh	PA		
Gough; Albert H.	Glenshaw	PA		
Giuliano; Kenneth A.	Pittsburgh	PA		

US-CL-CURRENT: 435/7.21, 382/255, 435/288.4, 435/375, 435/377, 435/4, 435/6,  
435/7.1, 435/7.2, 435/7.5, 436/10, 436/164, 436/166, 436/17, 436/172, 436/174,  
436/517, 436/546, 436/63

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn D](#)

---

 6. Document ID: US 6716588 B2

L2: Entry 6 of 38

File: USPT

Apr 6, 2004

US-PAT-NO: 6716588  
DOCUMENT-IDENTIFIER: US 6716588 B2

TITLE: System for cell-based screening

DATE-ISSUED: April 6, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sammak; Paul	Pittsburgh	PA		
Duensing; Thomas D.	Gibsonia	PA		
Rubin; Richard A.	Pittsburgh	PA		

US-CL-CURRENT: 435/7.2, 356/300, 356/326, 356/328, 382/133, 382/141, 435/288.3,  
435/288.4, 435/7.21, 435/7.23, 436/164, 436/172, 436/63

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn D](#)

---

 7. Document ID: US 6710195 B2

L2: Entry 7 of 38

File: USPT

Mar 23, 2004

US-PAT-NO: 6710195  
DOCUMENT-IDENTIFIER: US 6710195 B2

TITLE: Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions

DATE-ISSUED: March 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Joshi-Hangal; Rajashree	Union City	CA		
Rubinfeld; Joseph	Danville	CA		
Redkar; Sanjeev	Union City	CA		
Gore; Ashok Y.	San Ramon	CA		

US-CL-CURRENT: 554/132

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn](#)

---

8. Document ID: US 6671624 B1

L2: Entry 8 of 38

File: USPT

Dec 30, 2003

US-PAT-NO: 6671624

DOCUMENT-IDENTIFIER: US 6671624 B1

TITLE: Machine readable storage media for detecting distribution of macromolecules between nucleus and cytoplasm in cells

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dunlay; R. Terry	Pittsburg	PA		
Taylor; D. Lansing	Pittsburg	PA		
Gough; Albert H.	Pittsburg	PA		
Giuliano; Kenneth A.	Pittsburg	PA		

US-CL-CURRENT: 702/19; 382/133, 422/68.1, 435/4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Drawn](#)

---

9. Document ID: US 6667048 B1

L2: Entry 9 of 38

File: USPT

Dec 23, 2003

US-PAT-NO: 6667048

DOCUMENT-IDENTIFIER: US 6667048 B1

TITLE: Emulsion vehicle for poorly soluble drugs

DATE-ISSUED: December 23, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lambert; Karel J.	Woodinville	WA		
Constantinides; Panayiotis P.	Bothell	WA		
Quay; Steven C.	Edmonds	WA		

US-CL-CURRENT: 424/405; 514/938, 514/975

[Full](#) | 
 [Title](#) | 
 [Citation](#) | 
 [Front](#) | 
 [Review](#) | 
 [Classification](#) | 
 [Date](#) | 
 [Reference](#) | 
 [Sequences](#) | 
 [Attachments](#) | 
 [Claims](#) | 
 [KMC](#) | 
 [Draw. De](#)

10. Document ID: US 6660286 B1

L2: Entry 10 of 38

File: USPT

Dec 9, 2003

US-PAT-NO: 6660286

DOCUMENT-IDENTIFIER: US 6660286 B1

TITLE: Emulsion vehicle for poorly soluble drugs

DATE-ISSUED: December 9, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lambert; Karel J.	Woodinville	WA		
Constantinides; Panayiotis P.	Bothell	WA		
Tustian; Alexander K.	Bothell	WA		
Quay; Steven C.	Edmonds	WA		

US-CL-CURRENT: 424/405; 514/938

[Full](#) | 
 [Title](#) | 
 [Citation](#) | 
 [Front](#) | 
 [Review](#) | 
 [Classification](#) | 
 [Date](#) | 
 [Reference](#) | 
 [Sequences](#) | 
 [Attachments](#) | 
 [Claims](#) | 
 [KMC](#) | 
 [Draw. De](#)

11. Document ID: US 6559139 B1

L2: Entry 11 of 38

File: USPT

May 6, 2003

US-PAT-NO: 6559139

DOCUMENT-IDENTIFIER: US 6559139 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Combination chemotherapy

DATE-ISSUED: May 6, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Candace S.	Pittsburgh	PA		
Trump; Donald L.	Pittsburgh	PA		

US-CL-CURRENT: 514/168; 514/110, 514/167, 514/170, 514/449, 514/653

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

12. Document ID: US 6544544 B2

L2: Entry 12 of 38

File: USPT

Apr 8, 2003

US-PAT-NO: 6544544

DOCUMENT-IDENTIFIER: US 6544544 B2

TITLE: Anti-angiogenic compositions and methods of use

DATE-ISSUED: April 8, 2003

## INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA
Arsenault; A. Larry	Paris			CA

US-CL-CURRENT: 424/424; 424/426, 424/501, 424/502

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

13. Document ID: US 6541509 B2

L2: Entry 13 of 38

File: USPT

Apr 1, 2003

US-PAT-NO: 6541509

DOCUMENT-IDENTIFIER: US 6541509 B2

TITLE: Method for treating neoplasia using combination chemotherapy

DATE-ISSUED: April 1, 2003

## INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Horwitz; Susan B.	Larchmont	NY		
McDaid; Hayley M.	Bronx	NY		
Martello; Laura A.	Franklin Square	NY		

US-CL-CURRENT: 514/449; 514/459, 514/460, 514/908, 514/922

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

14. Document ID: US 6506411 B2

L2: Entry 14 of 38

File: USPT

Jan 14, 2003

US-PAT-NO: 6506411  
DOCUMENT-IDENTIFIER: US 6506411 B2

TITLE: Anti-angiogenic compositions and methods of use

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA
Arsenault; A. Larry	Paris			CA

US-CL-CURRENT: 424/501; 424/502

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [Drawn De](#)

---

15. Document ID: US 6458373 B1

L2: Entry 15 of 38

File: USPT

Oct 1, 2002

US-PAT-NO: 6458373

DOCUMENT-IDENTIFIER: US 6458373 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Emulsion vehicle for poorly soluble drugs

DATE-ISSUED: October 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lambert; Karel J.	Woodinville	WA		
Constantinides; Panayiotis P.	Bothell	WA		
Quay; Steven C.	Edmonds	WA		

US-CL-CURRENT: 424/405; 424/408, 424/455, 424/486, 514/511, 514/938

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KOMC](#) | [Drawn De](#)

---

16. Document ID: US 6440393 B1

L2: Entry 16 of 38

File: USPT

Aug 27, 2002

US-PAT-NO: 6440393

DOCUMENT-IDENTIFIER: US 6440393 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Carbon dioxide enhancement of inhalation therapy

DATE-ISSUED: August 27, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Waldrep; J. Clifford	The Woodlands	TX		
Knight; J. Vernon	Houston	TX		
Koshkina; Nadezhda	Houston	TX		

US-CL-CURRENT: 424/45; 424/1.13, 424/1.21, 424/450, 424/458

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn D](#)

17. Document ID: US 6416959 B1

L2: Entry 17 of 38

File: USPT

Jul 9, 2002

US-PAT-NO: 6416959

DOCUMENT-IDENTIFIER: US 6416959 B1

TITLE: System for cell-based screening

DATE-ISSUED: July 9, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Giuliano; Kenneth	Pittsburgh	PA	15209	
Kapur; Ravi	Gibsonia	PA	15044	

US-CL-CURRENT: 435/7.2; 250/201.3, 348/345, 356/300, 356/326, 356/328, 382/141,  
382/255, 435/288.3, 435/288.4, 435/29, 435/40.5, 435/40.51, 435/7.21, 436/172,  
436/546, 436/800, 436/809

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn D](#)

18. Document ID: US 6388112 B1

L2: Entry 18 of 38

File: USPT

May 14, 2002

US-PAT-NO: 6388112

DOCUMENT-IDENTIFIER: US 6388112 B1

TITLE: Process for purification of solvents useful in the preparation of pharmaceutical compositions

DATE-ISSUED: May 14, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anevski; Phillip J.	St. Louis	MO		

US-CL-CURRENT: 554/191

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw](#)

19. Document ID: US 6348491 B1

L2: Entry 19 of 38

File: USPT

Feb 19, 2002

US-PAT-NO: 6348491

DOCUMENT-IDENTIFIER: US 6348491 B1

TITLE: Oil-in-water emulsion for encapsulating paclitaxel

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chu; I-Ming	Hsinchu			TW
Wang; Tzy-Rong	Tainan			TW

US-CL-CURRENT: 514/449; 514/76

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw](#)

20. Document ID: US 6306894 B1

L2: Entry 20 of 38

File: USPT

Oct 23, 2001

US-PAT-NO: 6306894

DOCUMENT-IDENTIFIER: US 6306894 B1

\*\* See image for Certificate of Correction \*\*

TITLE: Injectable composition

DATE-ISSUED: October 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carver; David	Boulder	CO		
Prout; Timothy	Erie	CO		
Ewald; Hernita	Denver	CO		
Elliott; Robyn	Langwarrin			AU
Handreck; Paul	Glen Iris			AU

US-CL-CURRENT: 514/449

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw](#)

21. Document ID: US 6306166 B1

L2: Entry 21 of 38

File: USPT

Oct 23, 2001

US-PAT-NO: 6306166

DOCUMENT-IDENTIFIER: US 6306166 B1

TITLE: Loading and release of water-insoluble drugs

DATE-ISSUED: October 23, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barry; James J.	Marlboro	MA		
Palassis; Maria	Wellesley	MA		

US-CL-CURRENT: 623/1.46; 623/1.42

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">SEQUENCES</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KIMC</a>	<a href="#">Draw. D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	-------------------------

 22. Document ID: US 6229027 B1

L2: Entry 22 of 38

File: USPT

May 8, 2001

US-PAT-NO: 6229027

DOCUMENT-IDENTIFIER: US 6229027 B1

TITLE: Process for manufacturing paclitaxel and 13-acetyl-9-dihydrobaccatin IV

DATE-ISSUED: May 8, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Liu; Jian	Fredericton, New Brunswick			CA

US-CL-CURRENT: 549/510

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">SEQUENCES</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KIMC</a>	<a href="#">Draw. D</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	-------------------------

 23. Document ID: US 6201072 B1

L2: Entry 23 of 38

File: USPT

Mar 13, 2001

US-PAT-NO: 6201072

DOCUMENT-IDENTIFIER: US 6201072 B1

TITLE: Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

DATE-ISSUED: March 13, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rathi; Ramesh C.	Salt Lake City	UT		

Zentner; Gaylen M.	Salt Lake City	UT
Jeong; Byeongmoon	Salt Lake City	UT

US-CL-CURRENT: 525/415; 424/425, 424/426, 424/486, 424/85.1, 424/85.2, 514/2,  
528/354

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw. D](#)

24. Document ID: US 6140359 A

L2: Entry 24 of 38

File: USPT

Oct 31, 2000

US-PAT-NO: 6140359

DOCUMENT-IDENTIFIER: US 6140359 A

\*\* See image for Certificate of Correction \*\*

TITLE: Injectable composition

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Carver; David	Boulder	CO		
Prout; Timothy	Erie	CO		
Ewald; Hernita	Denver	CO		
Elliott; Robyn	Victoria			AU
Handreck; Paul	Victoria			AU

US-CL-CURRENT: 514/449

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw. D](#)

25. Document ID: US 6117949 A

L2: Entry 25 of 38

File: USPT

Sep 12, 2000

US-PAT-NO: 6117949

DOCUMENT-IDENTIFIER: US 6117949 A

TITLE: Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

DATE-ISSUED: September 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rathi; Ramesh C.	Salt Lake City	UT		
Zentner; Gaylen M.	Salt Lake City	UT		
Jeong; Byeongmoon	Salt Lake City	UT		

US-CL-CURRENT: 525/415; 424/425, 424/426, 424/486, 424/501, 528/354

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

 26. Document ID: US 6087350 A

L2: Entry 26 of 38

File: USPT

Jul 11, 2000

US-PAT-NO: 6087350

DOCUMENT-IDENTIFIER: US 6087350 A

TITLE: Use of pretreatment chemicals to enhance efficacy of cytotoxic agents

DATE-ISSUED: July 11, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Candace S.	Pittsburg	PA		
Trump; Donald	Pittsburg	PA		

US-CL-CURRENT: 514/168; 514/110, 514/167, 514/170, 514/23, 514/449, 514/653

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

 27. Document ID: US 6004573 A

L2: Entry 27 of 38

File: USPT

Dec 21, 1999

US-PAT-NO: 6004573

DOCUMENT-IDENTIFIER: US 6004573 A

TITLE: Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

DATE-ISSUED: December 21, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rathi; Ramesh C.	Salt Lake City	UT		
Zentner; Gaylen M.	Salt Lake City	UT		

US-CL-CURRENT: 424/426; 424/428, 424/430, 424/434, 424/435, 424/436, 424/437,  
424/443, 424/449, 424/451, 424/464

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

---

 28. Document ID: US 5994341 A

L2: Entry 28 of 38

File: USPT

Nov 30, 1999

US-PAT-NO: 5994341  
DOCUMENT-IDENTIFIER: US 5994341 A

TITLE: Anti-angiogenic Compositions and methods for the treatment of arthritis

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA
Arsenault; A. Larry	Paris			CA

US-CL-CURRENT: 514/449; 514/250, 514/825, 514/886

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn De](#)

---

29. Document ID: US 5922754 A

L2: Entry 29 of 38

File: USPT

Jul 13, 1999

US-PAT-NO: 5922754

DOCUMENT-IDENTIFIER: US 5922754 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Pharmaceutical compositions containing paclitaxel

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burchett; Mark K.	Waukegan	IL		
Coddington; Cynthia A.	Gurnee	IL		
Raghavan; Rajagopalan	Grayslake	IL		
Speicher; Earl R.	Buffalo Grove	IL		

US-CL-CURRENT: 514/449

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KIMC](#) | [Drawn De](#)

---

30. Document ID: US 5886026 A

L2: Entry 30 of 38

File: USPT

Mar 23, 1999

US-PAT-NO: 5886026

DOCUMENT-IDENTIFIER: US 5886026 A

TITLE: Anti-angiogenic compositions and methods of use

DATE-ISSUED: March 23, 1999

## INVENTOR - INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hunter; William L.	Vancouver			CA
Machan; Lindsay S.	Vancouver			CA
Arsenault; A. Larry	Paris			CA

US-CL-CURRENT: 514/449[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [Claims](#) | [KMC](#) | [Draw. De](#)[Clear](#) | [Generate Collection](#) | [Print](#) | [Fwd Refs](#) | [Bkwd Refs](#) | [Generate OACS](#)

Terms	Documents
(paclitaxel) same sealed	38

Display Format: [-] [Change Format](#)[Previous Page](#)    [Next Page](#)    [Go to Doc#](#)